XLS — Xlife Sciences AG Income Statement
0.000.00%
- CH₣145.84m
- CH₣295.35m
- CH₣0.99m
- 31
- 30
- 42
- 22
Annual income statement for Xlife Sciences AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.515 | 0.397 | 0.806 | 1.03 | 0.988 |
Cost of Revenue | |||||
Gross Profit | 0.179 | -0.026 | 0.359 | 0.186 | 0.449 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.28 | 3.49 | 6.04 | 22 | 21.3 |
Operating Profit | -0.768 | -3.09 | -5.23 | -21 | -20.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.03 | 21.2 | 53.2 | 4.04 | 4.53 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.03 | 21.1 | 53.3 | 8.78 | 9.27 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1.05 | 21.5 | 53.4 | 14.3 | 14.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.05 | 21.5 | 53.4 | 14.3 | 14.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.3 | 3.6 | 8.66 | 1.97 | 2.08 |
Dividends per Share |